vorasidenib
servier
['vorasidenib', 'indigo']
some toughts about the indigo phase 3 trial, vorasidenib in idh1- or idh2-mutant low-grade glioma #asco2023 - setting = residual or recurrent disease
- primary ep = pfs = improved from 11.1 to 27.7 mo (16.6) here are some toughts 1/6 
Medicine, Oncology (sarcoma, H&N, CUP), Research = EBM, Epi, Policy #metaresearch @Hopitaux_unige (Geneva, CH), @vkprasadlab (UCSF). No COI. Views mine.